Shigeyuki Nishinaka
Director/Miembro de la Junta en MYOVANT SCIENCES LTD. .
Cargos activos de Shigeyuki Nishinaka
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | 01/01/2009 | - |
UROVANT SCIENCES LTD. | Director/Miembro de la Junta | 27/12/2019 | - |
Independent Dir/Board Member | 27/12/2019 | - | |
MYOVANT SCIENCES LTD. | Director/Miembro de la Junta | 22/10/2022 | - |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Director/Miembro de la Junta | - | - |
Meltin MMI KK
Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Director/Miembro de la Junta | - | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Director/Miembro de la Junta | - | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Director/Miembro de la Junta | 01/12/2019 | - |
Historial de carrera de Shigeyuki Nishinaka
Antiguos cargos conocidos de Shigeyuki Nishinaka.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Financial Services Agency | Corporate Officer/Principal | 01/01/2001 | - |
Formación de Shigeyuki Nishinaka.
Hiroshima University | Doctorate Degree |
Estadísticas
Internacional
Japón | 5 |
Estados Unidos | 4 |
Reino Unido | 3 |
Operativa
Director/Board Member | 6 |
Corporate Officer/Principal | 2 |
Independent Dir/Board Member | 1 |
Sectorial
Health Technology | 8 |
Consumer Services | 2 |
Government | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
SUMITOMO PHARMA CO., LTD. | Health Technology |
Empresas privadas | 7 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Financial Services Agency | Government |
Meltin MMI KK
Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Health Technology |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Shigeyuki Nishinaka
- Experiencia